Celsius Therapeutics was a Cambridge, Massachusetts-based biotechnology company that pioneered the integration of machine learning and single-cell genomics to discover novel therapeutic targets and develop drugs for serious diseases. Founded in 2018, Celsius developed a distinctive platform that leveraged large-scale genomic data with artificial intelligence to identify driver genes and validate targets with unprecedented precision.
In August 2023, Celsius was acquired by Roche for approximately $2.5 billion, one of the largest acquisitions of an AI-driven biotech company at the time[roche2023]. The acquisition reflects the growing importance of AI and single-cell genomics in pharmaceutical R&D and validates Celsius's approach to drug discovery[taylor2020].
| Attribute | Value |
|---|---|
| Headquarters | Cambridge, Massachusetts, USA |
| Founded | 2018 |
| Acquired by | Roche (August 2023) |
| Acquisition price | ~$2.5 billion |
| Focus | AI-driven drug discovery, immunotherapy |
| Employees | ~100 (at acquisition) |
Celsius operated as an independent company from 2018 to 2023, developing its platform and advancing programs through Series A, B, and C funding rounds before going public on NASDAQ in 2021 (ticker: CELU).
Celsius's platform centered on single-cell genomics, a revolutionary approach that enables analysis of gene expression in individual cells rather than bulk tissue samples:
This approach enabled Celsius to identify cell-type specific targets that would be missed in traditional bulk tissue analysis, revealing novel therapeutic opportunities in the tumor microenvironment and inflamed tissues[regev2017; @zhou2019].
Celsius employed sophisticated machine learning algorithms to analyze the massive datasets generated by single-cell genomics:
The platform was designed to move from data to validated target in months rather than years, dramatically accelerating the traditional drug discovery timeline[jiang2024].
Celsius focused on several target classes amenable to antibody-based modulation:
Celsius's initial focus was on cancer immunotherapy:
The company generated multiple preclinical candidates targeting novel mechanisms.
Beyond oncology, Celsius applied its platform to autoimmune conditions:
Celsius also pursued fibrotic disease targets:
Celsius advanced multiple programs through its pipeline:
| Program | Target Class | Indication | Stage |
|---|---|---|---|
| CELU-001 | Immune modulator | Solid tumors | Preclinical |
| CELU-002 | Cell surface protein | Autoimmune | Discovery |
| CELU-003 | Signaling molecule | Fibrosis | Discovery |
| CELU-004 | Checkpoint | Oncology | Lead optimization |
The company had disclosed plans to advance at least two programs into IND-enabling studies by 2024.
Celsius's platform integrated multiple data modalities:
A key differentiator was Celsius's focus on disease tissue rather than cell lines or animal models:
This approach increased the probability of identifying clinically relevant targets.
Celsius implemented rigorous target validation:
Celsius operated with a hybrid approach:
The company raised over $300 million in funding before the Roche acquisition:
| Round | Year | Amount | Investors |
|---|---|---|---|
| Series A | 2019 | $45M | Third Rock, GV |
| Series B | 2020 | $63M | ARCH, Polaris |
| Series C | 2021 | $95M | Multiple |
| IPO | 2021 | $115M | Nasdaq |
In August 2023, Roche announced the acquisition of Celsius for $2.5 billion ($7.05 per share), representing a substantial premium to Celsius's pre-announcement stock price:
Following the acquisition, Celsius's operations were integrated into Roche's R&D organization:
Celsius represents a significant milestone in the AI drug discovery space: